Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) delivers innovative medical device solutions addressing critical healthcare challenges in pain management, recovery, and digestive health. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and clinical advancements.
Access official press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnerships. Track Avanos Medical’s progress in advancing non-opioid therapies and life-sustaining nutritional support systems designed for hospital and home care settings.
Key updates include developments in cold compression technology, feeding tube innovations, and operational efficiency initiatives under the company’s ongoing transformation. All content is sourced directly from Avanos Medical and verified financial disclosures to ensure accuracy.
Bookmark this page for streamlined access to AVNS news that impacts clinical practice and investment decisions. Check regularly for updates on breakthrough medical technologies and their global healthcare applications.
Avanos Medical (NYSE: AVNS) will host a conference call on May 3, 2023, at 9 a.m. ET, to discuss its financial results and business updates for the first quarter of 2023. A news release detailing these results will be issued before the market opens on the same day. The call will be led by Joe Woody, CEO, and Michael Greiner, CFO. Investors can join the conference call by dialing 877-240-5772 in the United States. A simultaneous webcast and presentation will also be available on the Avanos Medical website. A replay will be accessible post-call for one week. Headquartered in Alpharetta, Georgia, Avanos Medical focuses on delivering medical device solutions that enhance patient recovery.
Avanos Medical, Inc. (NYSE: AVNS) announced that Michael Greiner, CFO and Chief Transformation Officer, will participate in a fireside chat at the 2023 virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 22 at 9:45 a.m. ET. A webcast of the presentation will be available in the Investors section on Avanos' website and will be archived for later access. Avanos focuses on clinically superior medical devices, providing vital nutrition solutions and reducing opioid use during patient recovery. The company is headquartered in Alpharetta, Georgia, and holds leading market positions across its product categories.
Avanos Medical, Inc. (NYSE: AVNS) announced the appointment of Dr. Lisa Egbuonu-Davis as an independent member of its board of directors, effective March 6, 2023. Egbuonu-Davis, who previously held senior roles at Sanofi and co-founded ROI Squared, brings extensive experience in healthcare strategy and operations. Avanos board chair Gary Blackford expressed optimism about her contributions to the company’s mission of providing innovative healthcare solutions, particularly in reducing opioid use. With Egbuonu-Davis's addition, the board now has six directors, including five independents and two women.
Avanos Medical, Inc. (NYSE: AVNS) reported strong fourth quarter and full-year 2022 results, with net sales of $217 million for Q4, up 12% year-over-year, and full-year net sales reaching $820 million, a 10% increase. Diluted EPS for Q4 was $0.36, compared to $0.24 a year earlier, while adjusted diluted EPS rose to $0.60 from $0.50. The company reported a free cash flow of $29 million in Q4 and $72 million for the year. Avanos is implementing a three-year transformation plan, targeting cost savings of $45-$55 million, amid ongoing developments in its product portfolio and operational efficiencies.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
